Elizabeth Rossin is an Ophthalmology physician affiliated with Broad Institute. OpenAlex indexes 105 publications with 10,214 citations (h-index 27). By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
243 Charles St
Boston, MA 02114
Telephone
617-573-3416Registry record last updated 25 Jun 2018.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Research LLCProgram year20251 payment$80,000openpaymentsdata.cms.gov ↗
- Alcon Vision LLCProgram year20252 payments
- Genentech, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
77.7%Corticosteroid34.7%Prednisolone Acetate100%Part D≥24 patientsCarbonic Anhydrase Inhibitor29.8%Dorzolamide-Timolol61%Dorzolamide Hcl39%Part D<11 patients+ 1 more class in this area
Musculoskeletal
22.3%Cyclooxygenase Inhibitor22.3%Ketorolac Tromethamine100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Genetics of central serous chorioretinopathy and choroidal thickening
Massachusetts Eye and Ear Infirmary
FY2026$277,072K23EY035342 - Genetics of central serous chorioretinopathy and choroidal thickening
Massachusetts Eye and Ear Infirmary
FY2025$276,856K23EY035342 - Genetics of central serous chorioretinopathy and choroidal thickening
Massachusetts Eye and Ear Infirmary
FY2024$277,050K23EY035342
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Low population penetrance of variants associated with inherited retinal degenerations
The American Journal of Human Genetics
2025 - An mRNA-encoded dominant-negative inhibitor of transcription factor RUNX1 suppresses vitreoretinal disease in experimental models
Science Translational Medicine
2024 - Targeting the Tie-2 Receptor With Faricimab in Central Serous Chorioretinopathy: A Case Series Motivated by a Genetic Finding
American Journal of Ophthalmology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Alan Mullen, MD, PhD
Broad Institute
Benjamin Ebert, MD
Broad Institute
Susan Redline, MD
Broad Institute
Patrick Ellinor, MD, PhD
Broad Institute
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Richard Spaide, MD
Vitreous Retina Macula Consultants of New York
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”